Blog

T cells

How simpler implementations enable complex cell and gene therapies

After spending 12 years working in the biopharmaceutical industry – three of those here at Vineti – I’ve learned first-hand that cell and gene therapies (CGTs) present a unique environment for software implementation.st

Read More
December 16, 2021

How integrated digital systems solve key challenges with cell and gene therapies (CGTs)

One patient. One cell therapy. Ten or more distinct digital systems.
That’s often the number of heterogeneous digital systems across care sites, manufacturers, and…

December 8, 2021

Be The Match BioTherapies® and Vineti collaborate to develop innovative, integrated supply chain management solutions for cell and gene therapies

MINNEAPOLIS, Minn. and SAN FRANCISCO, Calif, December 08, 2021 - Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and…

November 15, 2021

Preparing for Cell and Gene Therapy 3.0

Patient data is mission-critical data — especially in cell and gene therapy.

In cell and gene therapy (CGT), the patient is the process is the…

November 11, 2021

Must-watch: Vineti’s Women in Tech panel discussion

ers across healthcare and technology! The event was moderated by Kat Noren, SVP of People and Places at Vineti, with panelists including Heidi Rozen, Partner…

November 1, 2021

Patient data – the unique role in cell and gene therapies (CGTs)

Patient data is mission-critical data — especially in cell and gene therapy.

In cell and gene therapy (CGT), the patient is the process is the…

November 1, 2021

Patient data – why it is critical for cell and gene therapy stakeholders

The first blog post in this series provided an overview of how the advanced therapies supply chain is different from traditional and biologic drug products…

November 1, 2021

Patient data – unique challenges, critical uses in the cell therapy value chain

The previous two blog posts in this series provided an overview of why patient-related data matters in cell therapy and gene therapy (CGTs), and how…

November 1, 2021

Integrated patient data – the future of advanced therapies

The cell and gene therapy (CGT) sector is poised for exponential growth — which will come in novel ways that reflect the unique nature of…

October 19, 2021

Autolomous and Vineti form strategic partnership to deliver end to end supply chain management solutions for cell and gene therapy sector

Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of leading digital enterprise platforms…

October 13, 2021

Körber and Vineti Announce Partnership to Provide Improved Manufacturing Performance and Visibility Globally for Cell and Gene-Based Therapies

Körber, the leading MES supplier for pharma and biotech, and Vineti, the world’s only enterprise software platform supporting supply chain orchestration for clinical and commercial…

September 7, 2021

Life Sciences cybersecurity, knowing your first line of defense and continuously improving it

Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…

August 31, 2021

Key industry and government regulations provide a cybersecurity foundation in advanced therapies

Pharmaceutical and biotech companies suffer more security breaches than any other industry1 — with greater than 20% of companies in the pharmaceutical sector having been…